Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder

By WebmasterApril 13, 2017November 1st, 2024No Comments

Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder

Previous PostOptofluidics Announces Name Change to Halo Labs
Next PostMD Anderson, Oncora Medical team up to fight cancer with precision medicine alliance